Search Results
61 items found for "Ben Jones"
Programs (1)
- Applying Pharmacology to Drug Discovery
allows predictions of drug activity in all physiological systems, not only the system where testing is done
Posts (37)
- Dr. Ben Myers - Dr. GPCR Podcast
Ben Myers!
- 📰 GPCR Weekly News, June 3 to June 9, 2024
Deadline 1st round priority: June 24th / 2nd round: July 22th Do you have an artistic side? Let’s dive into the Classified GPCR News from June 3rd to June 9th, 2024. GPCRs and Emotional Pain: Exploring Non-Narcotic Pathways to Relief GPCR Events, Meetings, and Webinars June 9 - 14, 2024 | 2024 Phosphorylation and G-Protein Mediated Signaling Networks June 25 - 29, 2024 | FENS
- Hop in the Time Machine with GPCR: Unraveling the Future of Research! ⦿ Nov 24 - Dec 1, 2024
tagging and interrogation of GPCR co-internalization Kilian Roßmann , Ramona Birke , Joshua Levitz , Ben Jones , Johannes Broichhagen Design of allosteric modulators that change GPCR G protein subtype selectivity 2025 | AACR Annual Meeting 2025 May 12 - 15, 2025 | PEGS 2025 May 20 - 22, 2025 | SLAS Europe 2025 June
Other Pages (23)
- Ep 136 with Murat Tunaboylu & Ben Holland
GPCR Podcast << Back to podcast list Murat Tunaboylu & Ben Holland About Murat Tunaboylu "Murat Tunaboylu GPCR About Ben Holland "Ben gained his masters in Engineering Science from Oxford, taking a specialisation nearly 10 years, applying it to antibody generation, analysis, and property prediction since 2017" Ben
- Ep 52 with Dr. Benjamin Myers
Benjamin Myers Ben Myers is an assistant professor at the University of Utah School of Medicine in Salt Ben’s research focuses on Smoothened and other class F GPCRs which play essential roles in embryonic More recently, Ben’s lab has begun studying GPCR signaling pathways that operate within the primary cilium Ben studied developmental and cancer signaling as a postdoctoral fellow with Philip Beachy at Stanford Prior to that, Ben received his Ph.D. from UCSF in 2008, where he worked with David Julius on the structure
- Bispecific antibodies targeting BCMA or GPRC5D are highly effective in relapsed myeloma after CAR T-cell therapy
Aina Oliver-Cáldes, Kristin Rathje, James A Davis, David Fandrei, Vladan Vucinic, Soraya Kharboutli, Ben-Niklas